Aldosterone and pressor responses to angiotensin II in primary hyperparathyroidism. 1989

F Fallo, and S Rocco, and U Pagotto, and M Zangari, and G Luisetto, and F Mantero
Institute of Semeiotica Medica, University of Padua, Italy.

The aim of this study was to assess the effect of hypercalcaemia due to primary hyperparathyroidism on the pressor and aldosterone responses to angiotensin II (Ang II) infusion. Five patients with hyperparathyroidism were studied, before and after parathyroidectomy, and were compared with five normal subjects. After 30 min of equilibration, Asp1-Val5 Ang II was infused in all subjects at stepwise increasing dose rates of 2 and 4 ng/kg per min for 30 min each. In the hyperparathyroid patients the baseline levels of plasma parathyroid hormone and calcium were significantly higher than in the controls, and returned to normal after the parathyroidectomy; plasma aldosterone and renin activity were normal both before and after the parathyroidectomy. Two hyperparathyroid patients had high blood pressure levels, which were normalized after surgery. The increase in the aldosterone response from baseline at each time point of the Ang II infusion was greater in the hyperparathyroid patients before than after the operation (P less than 0.05), and greater than in the normals (P less than 0.05). No difference in the increased response of systolic or diastolic blood pressure was observed between the hyperparathyroid patients, either before or after the parathyroidectomy, and the normal subjects. High levels of extracellular calcium or parathyroid hormone, or both, might play a primary role in the aldosterone hyper-responsiveness to Ang II in the hyperparathyroid patients. The similar pressor response to Ang II in hyperparathyroid patients and the normal subjects suggests that hypercalcaemia does not potentiate the vasoconstrictive action of Ang II.

UI MeSH Term Description Entries
D006961 Hyperparathyroidism A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010280 Parathyroid Glands Two pairs of small oval-shaped glands located in the front and the base of the NECK and adjacent to the two lobes of THYROID GLAND. They secrete PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body. Gland, Parathyroid,Glands, Parathyroid,Parathyroid Gland
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006934 Hypercalcemia Abnormally high level of calcium in the blood. Milk-Alkali Syndrome,Hypercalcemias,Milk Alkali Syndrome,Syndrome, Milk-Alkali

Related Publications

F Fallo, and S Rocco, and U Pagotto, and M Zangari, and G Luisetto, and F Mantero
June 1990, Hypertension (Dallas, Tex. : 1979),
F Fallo, and S Rocco, and U Pagotto, and M Zangari, and G Luisetto, and F Mantero
September 1995, Journal of cardiovascular pharmacology,
F Fallo, and S Rocco, and U Pagotto, and M Zangari, and G Luisetto, and F Mantero
December 1992, Acta psychiatrica Scandinavica,
F Fallo, and S Rocco, and U Pagotto, and M Zangari, and G Luisetto, and F Mantero
June 1971, The Journal of pharmacy and pharmacology,
F Fallo, and S Rocco, and U Pagotto, and M Zangari, and G Luisetto, and F Mantero
January 1983, European journal of clinical pharmacology,
F Fallo, and S Rocco, and U Pagotto, and M Zangari, and G Luisetto, and F Mantero
June 1982, Metabolism: clinical and experimental,
F Fallo, and S Rocco, and U Pagotto, and M Zangari, and G Luisetto, and F Mantero
January 1990, The American journal of physiology,
F Fallo, and S Rocco, and U Pagotto, and M Zangari, and G Luisetto, and F Mantero
June 1975, Clinical science and molecular medicine. Supplement,
F Fallo, and S Rocco, and U Pagotto, and M Zangari, and G Luisetto, and F Mantero
January 1982, Neuroendocrinology,
F Fallo, and S Rocco, and U Pagotto, and M Zangari, and G Luisetto, and F Mantero
March 1999, Metabolism: clinical and experimental,
Copied contents to your clipboard!